Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEVONORGESTREL

All products: general benefit

Other products in the same Health Canada class (G02B) — coverage varies; not interchangeable

  • Ethinyl estradiol + etonogestrel (Nuvaring): not a benefit

Kyleena · DIN 02459523 · 19.5mg · Insert

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kyleena · DIN 02459523 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2018-05-31 Health Canada: Marketed since 2017-01-10 · brand KYLEENA · ATC G02BA03 PLASTIC IUD WITH PROGESTOGENS · form Insert (extended-release) · route Intrauterine · ingredients LEVONORGESTREL 19.5 MG · company Bayer inc · schedule Prescription
Check this DIN again · Health Canada product record

Kyleena: Formulary list price $355.5800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $355.5800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94684 · Verify on the e-Formulary ↗ (DIN 02459523)

Source record
DIN 02459523: Kyleena Raw flags: sec3=Y Item: 681200002; group id 729; item number 1792; lccId None; manufacturer id BAY Source form: Insert; strength: 19.5mg Recorded listing: General benefit Source prices (unrounded): $355.5800; ministry $355.5800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459523 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94684
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL 68:12 Contraceptives

ETHINYL ESTRADIOL & ETONOGESTREL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.120mg & 0.015mg/24 hr · Slow Release Vag Ring

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg/10mcg & 10mcg · Tab-28 Tab Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications MIRENA (levonorgestrel-releasing intrauterine system) is indicated for: • conception control for maximum up to 8 years • treatment of idiopathic menorrhagia following appropriate diagnostic investigation for up to 5 years in individuals accepting the contraceptive effect of MIRENA 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: MIRENA has not been studied in individuals over the age of 65 years. No data are available to Health Canada, therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00081240.PDF PM date: 2025-07-30 Source product: MIRENA; DIN 02243005; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.